Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unravelling the Encapsulation of DNA and Other Biomolecules in HAp Microcalcifications of Human Breast Cancer Tissues by Raman Imaging.
Marro M, Rodríguez-Rivero AM, Araujo-Andrade C, Fernández-Figueras MT, Pérez-Roca L, Castellà E, Navinés J, Mariscal A, Julián JF, Turon P, Loza-Alvarez P. Marro M, et al. Among authors: perez roca l. Cancers (Basel). 2021 May 28;13(11):2658. doi: 10.3390/cancers13112658. Cancers (Basel). 2021. PMID: 34071374 Free PMC article.
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.
Felip E, Gutiérrez-Chamorro L, Gómez M, Garcia-Vidal E, Romeo M, Morán T, Layos L, Pérez-Roca L, Riveira-Muñoz E, Clotet B, Fernandez PL, Mesía R, Martínez-Cardús A, Ballana E, Margelí M. Felip E, et al. Among authors: perez roca l. Cancers (Basel). 2022 Jan 27;14(3):641. doi: 10.3390/cancers14030641. Cancers (Basel). 2022. PMID: 35158911 Free PMC article.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Gutiérrez-Chamorro L, Felip E, Castellà E, Quiroga V, Ezeonwumelu IJ, Angelats L, Esteve A, Perez-Roca L, Martínez-Cardús A, Fernandez PL, Ferrando-Díez A, Pous A, Bergamino M, Cirauqui B, Romeo M, Teruel I, Mesia R, Clotet B, Riveira-Muñoz E, Margelí M, Ballana E. Gutiérrez-Chamorro L, et al. Among authors: perez roca l. Cell Oncol (Dordr). 2024 Feb;47(1):189-208. doi: 10.1007/s13402-023-00862-1. Epub 2023 Sep 4. Cell Oncol (Dordr). 2024. PMID: 37667113 Free PMC article.
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Peñas R, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M. Rosell R, et al. Among authors: perez roca l. PLoS One. 2009;4(5):e5133. doi: 10.1371/journal.pone.0005133. Epub 2009 May 5. PLoS One. 2009. PMID: 19415121 Free PMC article. Clinical Trial.
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida G, Farabi R, Jassem J. Rosell R, et al. PLoS One. 2007 Nov 7;2(11):e1129. doi: 10.1371/journal.pone.0001129. PLoS One. 2007. PMID: 17987116 Free PMC article.
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Sorigue M, Oliveira A, Mercadal S, Tapia G, Climent F, Perez-Roca L, Lorences I, Domingo-Domenech E, Cabezon M, Navarro JT, Gonzalez-Barca E, Zamora L, Ribera JM, Sureda A, Armengol MP, Sancho JM. Sorigue M, et al. Among authors: perez roca l. Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25. Hematol Oncol. 2019. PMID: 31475375
14 results